Frequency, Predictors and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients with Symptomatic Atherosclerosis

COMMENTED

Atrial FibrillationLipid-Lowering Drugs

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

★ 3 Recommended and commented by Prof. Dr Isabella Sudano, Faculty Member

Atherosclerosis

Averna M, Banach M, Bruckert E, Drexel H, Farnier M, Gaita D, Magni P, März W, Masana L, Mello E Silva A, Reiner Z, Ros E, Vrablik M, Zambon A, Zamorano JL, Stock JK, Tokgözoğlu LS, Catapano AL

doi: 10.1016/j.atherosclerosis.2021.03.039

Thrombosis and Stroke

Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis

Lancet Haematol.

Dawwas GK, Brown J, Dietrich E, Park H

doi: 10.1016/S2352-

Heart, Artery and Coronary Diseases

Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease

Circulation.

Gurbel PA, Fox KAA, Tantry US, Ten Cate H, Weitz JI

doi: 10.1161/CIRCULATIONAHA.118.033580.

RECOMMENDED

Thrombosis and Stroke

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

N Engl J Med.

Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS; AVERT Investigators

doi: 10.1056/NEJMoa1814468.

Cardiac Arrest or DeathHeart, Artery and Coronary DiseasesMyocardial InfarctionThrombosis and StrokeTherapy and Intervention

Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction

J Am Heart Assoc.

Koskinas KC, Zanchin T, Klingenberg R, Gencer B, Temperli F, Baumbach A, Roffi M, Moschovitis A, Muller O, Tüller D, Stortecky S, Mach F, Lüscher TF, Matter CM, Pilgrim T, Heg D, Windecker S, Räber L

doi: 10.1161/JAHA.117.008085.

Thrombosis and Stroke

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

BMJ.

Khan F, Rahman A, Carrier M, Kearon C, Weitz JI, Schulman S, Couturaud F, Eichinger S, Kyrle PA, Becattini C, Agnelli G, Brighton TA, Lensing AWA, Prins MH, Sabri E, Hutton B, Pinede L, Cushman M, Palareti G, Wells GA, Prandoni P, Büller HR, Rodger MA, MARVELOUS Collaborators.

doi: 10.1136/bmj.l4363.

RECOMMENDED

Cardiovascular Risk and Diseases

Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Atherosclerosis

Belch JJF, Brodmann M, Baumgartner I, Binder CJ, Casula M, Heiss C, Kahan T, Parini P, Poredos P, Catapano AL, Tokgözoğlu L

doi: 10.1016/j.atherosclerosis.2021.09.022

Thrombosis and Stroke

Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study

Eur Heart J.

Ogdie A, Kay McGill N, Shin DB, Takeshita J, Jon Love T, Noe MH, Chiesa Fuxench ZC, Choi HK, Mehta NN, Gelfand JM

doi: 10.1093/eurheartj/ehx145.

Therapy and Intervention

Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial

Eur Heart J.

Serruys PW, Takahashi K, Chichareon P, Kogame N, Tomaniak M, Modolo R, Chang CC, Komiyama H, Soliman O, Wykrzykowska JJ, de Winter RJ, Ferrario M, Dominici M, Buszman P, Bolognese L, Tumscitz C, Benit E, Stoll HP, Hamm C, Steg PG, Onuma Y, Jüni P, Windecker S, Vranckx P, Colombo A, Valgimigli M

doi: 10.1093/eurheartj/ehz453.

Related content

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis

Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement

Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study

Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial